Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
189
-
Total 13F shares, excl. options
-
59.1M
-
Shares change
-
-804K
-
Total reported value, excl. options
-
$2.05B
-
Value change
-
-$21.7M
-
Put/Call ratio
-
5.26
-
Number of buys
-
88
-
Number of sells
-
-92
-
Price
-
$34.65
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q2 2024
220 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q2 2024.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 189 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.1M shares
of 62.2M outstanding shares and own 95.02% of the company stock.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (5.84M shares), BlackRock Inc. (5.76M shares), RTW INVESTMENTS, LP (5.29M shares), BVF INC/IL (3.32M shares), VANGUARD GROUP INC (3.24M shares), JOHNSON & JOHNSON (2.45M shares), STATE STREET CORP (2.08M shares), Jefferies Financial Group Inc. (2.04M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2M shares), and ADAR1 Capital Management, LLC (1.6M shares).
This table shows the top 189 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.